Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Cabometyx
Pharma
Exelixis joins Novartis on FDA waiting list in prostate cancer
The Cabometyx-Tecentriq combo showed a positive trend in overall survival in prostate cancer, yet the FDA wants more mature data.
Angus Liu
Jan 25, 2024 8:00am
Exelixis reveals Cabometyx data that led to early trial end
Oct 22, 2023 3:30am
Exelixis ends Cabometyx study after seeing dramatic improvements
Aug 24, 2023 12:54pm
Roche, Exelixis combo triumphs in prostate cancer trial
Aug 21, 2023 9:57am
Exelixis, Teva settle patent litigation with 2031 license
Jul 24, 2023 10:05am
ASCO: Merck's Keytruda, Roche's Tecentriq add to I-O failures
Jun 6, 2023 8:19am
